212890-86-3

Basic information

• Product Name: 1-Pyrrolidinecarboxylic acid, 2-(hydroxyMethyl)-4,4-diMethyl-, 1,1-diMethylethyl ester, (2S)-
• Synonyms: 1-Pyrrolidinecarboxylic acid, 2-(hydroxyMethyl)-4,4-diMethyl-, 1,1-diMethylethyl ester, (2S)-;(S)-tert-butyl 2-(hydroxymethyl)-4,4-dimethylpyrrolidine-1-carboxylate;tert-butyl (2S)-2-(hydroxymethyl)-4,4-dimethylpyrrolidine-1-carboxylate;tert-butyl (S)-2-(hydroxymethyl)-4,4- dimethylpyrrolidine-1-carboxylate
• CAS NO: 212890-86-3
• Molecular Formula: C₁₂H₂₃NO₃
• Molecular Weight: 229.31592
• EINECS: -0
• Mol File: 212890-86-3.mol

Chemical Properties

• Boiling Point: 303.9±15.0 °C(Predicted)
• Appearance: /
• Density: 1.024±0.06 g/cm3(Predicted)
• PKA: 14.77±0.10(Predicted)
• CAS DataBase Reference: 1-Pyrrolidinecarboxylic acid, 2-(hydroxyMethyl)-4,4-diMethyl-, 1,1-diMethylethyl ester, (2S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Pyrrolidinecarboxylic acid, 2-(hydroxyMethyl)-4,4-diMethyl-, 1,1-diMethylethyl ester, (2S)-(212890-86-3)
• EPA Substance Registry System: 1-Pyrrolidinecarboxylic acid, 2-(hydroxyMethyl)-4,4-diMethyl-, 1,1-diMethylethyl ester, (2S)-(212890-86-3)

Safety Data

• Hazardous Substances Data: 212890-86-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
1-Pyrrolidinecarboxylic acid, 2-(hydroxyMethyl)-4,4-diMethyl-, 1,1-diMethylethyl ester, (2S)is used as a chiral building block for the synthesis of various pharmaceutical ingredients and biologically active compounds. Its unique structure and properties make it a valuable intermediate in the production of drugs and other fine chemicals.
Used in Organic Synthesis:
In the field of organic synthesis, 1-Pyrrolidinecarboxylic acid, 2-(hydroxyMethyl)-4,4-diMethyl-, 1,1-diMethylethyl ester, (2S)is utilized as a key component in the synthesis of complex organic molecules. Its versatility and reactivity contribute to the development of novel compounds with potential applications in various industries.
Used in the Production of Fine Chemicals:
1-Pyrrolidinecarboxylic acid, 2-(hydroxyMethyl)-4,4-diMethyl-, 1,1-diMethylethyl ester, (2S)is also employed in the production of fine chemicals, where its unique properties and reactivity are harnessed to create high-quality specialty chemicals for various applications.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 212890-85-2 (S)-(+)-(4,4-dimethylpyrrolidin-2-yl)methan-1-ol 
• 144978-35-8 (S)-ethyl N-tert-butoxycarbonylpyroglutamate 
• 1001353-87-2 (2S)-1-(tert-butoxycarbonyl)-4,4-dimethylpyrrolidine-2-carboxylic acid 
• 138423-86-6 Methyl (2S)-1-(tert-bytoxycarbonyl)-4,4-dimethylprolinate 
• 221637-35-0 (S)-ethyl 4,4-dimethyl-5-oxopyrrolidine-2-carboxylate 
• 158392-80-4 1-tert-butyl 2-ethyl (2S)4,4-dimethyl-5-oxopyrrolidine-1,2-dicarboxylate 
• 156088-46-9 (5S)-3,3-dimethyl-5-hydroxymethylpyrrolidin-2-one 

Downstream Products

• 212890-84-1 (S)-2-[(Diphenylphosphanyl)-methyl]-4,4-dimethyl-pyrrolidine 
• 212890-87-4 (S)-(-)-tert-butyl 2-[(diphenylphosphino)methyl]-4,4-dimethylpyrrolidinecarboxylate 
• 184699-47-6 (S)-(-)-tert-butyl 4,4-dimethyl-2-[((4-methylphenyl)sulfonyloxy)methyl]pyrrolidinecarboxylate 

Relevant articles and documents

MODULATORS OF HEMOGLOBIN FOR THE TREATMENT OF SICKLE CELL DISEASE

The present disclosure relates to compounds of the general formula (I) and pharmaceutical compositions containing them. The compounds are suitable as modulators of hemoglobin and thus useful in treating disorders mediated by hemoglobin such as sickle cell disease.

As hepatitis c inhibitor spiro compound and its use in medicine

The invention provides a spiro compound serving as a hepatitis c inhibitor and application thereof in a medicine. The compound is a compound as shown in a formula (I) or a stereisomer, a geometric isomer, a tautomer, nitric oxide, an aquo-complex, a solvate, a metabolite, pharmaceutically acceptable salt or prodrug of the compound as shown in the formula (I). The invention also provides a pharmaceutical composition containing the compound, application of the compound and the pharmaceutical composition in inhibition of HCV (Hepatitis C Virus) copy and HCV virus protein, as well as the application of the compound and the pharmaceutical composition in prevention, handling, treatment or relieving of HCV infection or hepatitis c disease for a patient. The formula I is as shown in the specification.

TETRACYCLIC INDOLE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION

Tetracyclic indole derivatives of formula (I), pharmaceutically acceptable salts and the pharmaceutical compositions thereof are provided, wherein A, A', G, R1, R15, U, V, V, W, W, X, X', Y, Y' are as defined in the invention. Use of these derivatives for treating hepatitis C virus (HCV) infection is also provided.

FUSED TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES

The present invention discloses novel Fused Tetracyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', G, R1, R15, U, V, V', W, W', X, X', Y and Y' are as defined herein. The present invention also discloses compositions comprising at least one Fused Tetracyclic Heterocycle Compound, and methods of using the Fused Tetracyclic Heterocycle Compounds for treating or preventing HCV infection in a patient.

TETRACYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Tetracyclic Indole Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', G, R1, R15, U, V, V', X, X', Y and Y' are as defined herein. The present invention also relates to compositions comprisingat least one Tetracyclic Indole Derivative, and methods of using the Tetracyclic Indole Derivatives for treating or preventing HCV infection in a patient.

TETRACYCLIC HETEROCYCLE COMPOUNDS FOR TREATING HEPATITIS C VIRAL INFECTION

Tetracyclic heterocycle compounds of formula (I) and pharmaceutically acceptable salts thereof are provided, wherein A, A', G, R1, R15, U, V, V', W, W, X, X', Y and Y' are as defined in the invention. The pharmaceutical compositions comprising these compounds and the use of the compounds for treating hepatitis C virus (HCV) infection are also provided.

FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Fused Tetracycle Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', B, G, R1, U, V, W, W', X, X', Y and Y' are as defined herein. The present invention also relates to compositions comprising at least one Fused Tetracycle Derivative, and methods of using the Fused Tetracycle Derivatives for treating or preventing HCV infection in a patient.

An external chiral amidophosphine ligand for asymmetric conjugate addition of organocopper

Two types of external, chiral amidophosphine ligands, 1-5, were prepared. Examination of their behavior in an asymmetric conjugate addition reaction of organocuprate revealed the possibility for steric tuning to realize high selectivity.

Structural requirements of an external, chiral amidophosphine ligand for asymmetric reaction of an organocopper reagent

Three types of an external, chiral amide ligand, 2-6, were prepared and examination of their behavior in an asymmetric conjugate addition reaction of lithium dimethylcuprate with chalcone revealed to possibility for steric tuning to realize high selectivity.